description
Powered by Eupheria Biotech
product line
MISSION®
form
lyophilized powder
esiRNA cDNA target sequence
ATTCACCCCCTGCAAAAATCGGGGCGACAATAGCTCACTGCCTACTTGCTGCAGGGAGATGAAAGGCTTTGCAGAAAGCTTTGAGCTCTGTGGGGGAACACACTAGAGAACCAAAAATGTGATTATATGGTGATATAAAAATCCCTTTCCTCTGTGTTTACCACCACCTGTCTTCCTGTAGACTTTTGTTCTGTCCCTGGGGTGTGTGAATTCCTACCCCGAACTGGAAGCCGGGAGTGGCAGACAGAATCACTATTTCAAGTTAAAGGATCTCTTTGAGAATGTGTTCTTCTGGCTGCAAAGGTCTGAGTTATTACGCTACATGACAACGTTTCGACATTTCACCGGCAACACCAAGAGGGTTTTTAGTGGCTTGGGTCTCCCCAGTGGGGGATAAGTCTTTTGTCATCAAGGAGGCAAATTGTCTCCCCAAGACAGCTCAAAATATCCACACCTCGGCAACAGTCTAAGATGAGAGCCTGTGACAGGTGGCAGCGCCCCCAGGTGGGGTACTGGCAT
Ensembl | human accession no.
NCBI accession no.
shipped in
ambient
storage temp.
−20°C
Quality Level
General description
MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
Legal Information
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
flash_point_f
Not applicable
flash_point_c
Not applicable
wgk
WGK 1
存储类别
12 - Non Combustible Liquids
法规信息
新产品
此项目有
Ina Nemet et al.
Cell, 180(5), 862-877 (2020-03-07)
Using untargeted metabolomics (n = 1,162 subjects), the plasma metabolite (m/z = 265.1188) phenylacetylglutamine (PAGln) was discovered and then shown in an independent cohort (n = 4,000 subjects) to be associated with cardiovascular disease (CVD) and incident major adverse cardiovascular events (myocardial infarction
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持